Bladder Cancer Detection Kit Market: Increasing prevalence of bladder cancer and demand for detection kitsis augmenting the market growth at a healthy CAGR of ~11.17% during the forecast period of 2021 to 2027
Bladder Cancer Detection Kit Market: by Sample Kit Technology [Fluorescence In Situ Hybridization (FISH), and Enzyme-Linked Immunosorbent Assay (ELISA)], by End User (Hospitals & Clinics and Diagnostic Centers), and by Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast to 2027
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/10669
Market Highlights
According to MRFR analysis, the global bladder cancer detection kit market is expected to register a CAGR of ~11.17% from 2021 to 2027and hold a value of USD ~322.4 million by 2027.
The global bladder cancer detection kit market is driven by several factors, such asthe increasing prevalence of bladder cancer worldwide, surge in mortality rate due to bladder cancer, rising demand for non-invasive detection of urothelial cancer, and growing aging population. Moreover, the market players are developing products and raising funds for marketing its product all across the world. The industry players are focusing on the expansion of their distribution network and supply chain to dominate the global bladder cancer detection kit market.
Regional Analysis
North America is expected to dominate the bladder cancer detection kit market, owing to the high prevalence of bladder cancer, adoption of technologically advanced products for bladder cancer detection, and presence of major industry players across the region. In addition, increased investments in R&D of the products by the government and private organizations have surged the level of competition among the market players. The prominent players are also involved in collaborations, partnerships, and high investments in R&D activities which are contributing to the market growth.
Segmentation
The global bladder cancer detection kit market has been segmented into technology and end user. By technology, the market has been segregated into Fluorescence In Situ Hybridization (FISH) Blood Sample Test Kit, Enzyme-Linked Immunosorbent Assay (ELISA), and others. The FISHsegment is expected to hold a considerable share of the market in 2020. The high demand for urine-based molecular test products,such as Abbott’s UroVysion Bladder Cancer Kit approved by the FDA to aid bladder cancer surveillance and assist with the diagnosis,will augment the market growth in the assessed period.
Key Players
Some of the key players in the global bladder cancer detection kit market are Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd. (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain), and Xiamen Boson Biotech Co., Ltd. (China)
留言